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Many epidemiologic studies suggest that pre- 
and postnatal exposure to persistent organic 
pollutants (POPs) can promote several adverse 
effects in children, such as altered neurode-
velopment (Eskenazi et al. 2008; Koopman-
Esseboom et al. 1996; Ribas-Fito et al. 2001; 
Rosas and Eskenazi 2008; Walkowiak et al. 
2001). Although environmental levels of most 
POPs declined after their use was restricted 
in many countries, these compounds are 
still found in most human tissues and blood 
samples. Moreover, some persistent chemi-
cals, such as polybrominated diphenyl ethers 
(PBDEs) and 1,1,1-trichloro-2,2-bis(p-
chloro  phenyl)ethane (p,p´-DDT), are still 
produced and widely used.
Prenatal and early postnatal periods are 
critical for the developing brain. Mild endo-
crine disruption during these time windows 
can lead to deficits in neuropsychological 
functions in infants, and these effects are 
specific to the time when hormonal dys-
regulation occurs (Zoeller and Rovet 2004). 
Therefore, timing of exposure to endocrine-
disrupting compounds during early stages of 
development is critical. Epidemiologic studies 
to date have relied on diverse biologic samples 
drawn prenatally, at birth, or postnatally to 
investigate relationships between exposure 
to POPs and various outcomes pertaining to 
health and development. Although multiple 
samples provide information on the overall 
exposure in infants, this approach is costly, 
time-consuming, and subject to ethical limita-
tions and might not capture some key events 
in the lifetime toxicokinetic profiles of POPs. 
Therefore, new exposure assessment tools to 
estimate complete toxicokinetic profiles in 
infants might broaden the scope of findings 
for specific periods of susceptibility.
Several studies have attempted to describe 
POP toxicokinetics in humans through vari-
ous modeling approaches. Ayotte et al. (2003) 
developed a statistical model to predict levels 
of PCB-153 in Inuit infants. Their multivari-
ate model that included maternal PCB-153 
plasma lipid concentration, breast-feeding 
duration, and the sum of two skin-fold thick-
nesses (an index of infant adipose tissue mass) 
explained 72% of PCB-153 infant plasma 
concentration variance at 6 months postpar-
tum. However, predictions were limited to a 
single compound at a specific age, and such 
data-based models might not be applicable 
to other ranges of exposure and populations 
because of genetic and life habit differences. 
Single-compartment first-order pharmacoki-
netic models were used by Lorber and Phillips 
(2002) and LaKind et al. (2000) to assess 
exposure to dioxin-like compounds through 
breast-feeding. Although these models gen-
erated toxicokinetic profiles in infants, they 
integrated infant body burden at birth and 
breast milk concentration as independent 
variables, an approach that would require the 
sampling of both media within an epidemio-
logic study context. Furthermore, such mod-
els do not allow estimations of POP levels in 
target tissues. 
Physiologically based pharmacokinetic 
(PBPK) modeling enables the estimation 
of tissue and blood POP levels based on 
physiologic parameters, such as organ vol-
ume and blood flow, as well as compound 
physicochemical properties. PBPK models 
have been developed to evaluate infant expo-
sure to 2,3,7,8-tetrachlorodibenzo-p-dioxin 
(TCDD) through breast-feeding (Ayotte 
et al. 1996; Gentry et al. 2003; Kreuzer et al. 
1997). Although this is a relevant approach 
to assess POP tissue dosimetry in humans, 
PBPK frameworks to date have not allowed 
the integration of individual physiologic 
characteristics (e.g., body mass index lifetime 
profiles), thus preventing their use within the 
context of epidemiologic studies. Moreover, 
no attempts were made to validate these 
models on a large scale using longitudinal 
POP measurements and on multiple persis-
tent chemicals. To generate individualized 
toxicokinetic profiles to be used within epi-
demiologic studies, we recently developed 
a PBPK framework to assess lifetime inter-
nal exposure to different POPs in women 
that is based on the physiology and repro-
ductive history of the subjects (Verner et al. 
2008). Based on this framework, the model 
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Ba c k g r o u n d: It has been suggested that pre- and postnatal exposure to persistent organic 
  pollutants (POPs) can promote several adverse effects in children, such as altered neurodevelopment. 
Epidemiologic studies to date have relied on the analysis of biological samples drawn pre- or post-
natally for exposure assessment, an approach that might not capture some key events in the toxico-
kinetics of POPs.
oBjectives: We aimed to build a generic physiologically based pharmacokinetic (PBPK) modeling 
framework for neutral POPs to assess infant toxicokinetic profiles and to validate the model using 
data on POP levels measured in mothers and infants from a Northern Québec Inuit population.
Me t h o d s : The PBPK model developed herein was based upon a previously published model to 
which an infant submodel was added. Using the model and maternal blood levels at the time of 
delivery, exposure to 1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene (p,p´-DDE), 1,1,1-trichloro-
2,2-bis(p-chlorophenyl)ethane (p,p´-DDT), hexachlorobenzene (HCB), β-hexachlorocyclohexane 
(β-HCH), 2,2´,3,4,4´,5´-hexachlorobiphenyl (PCB-138), 2,2´,4,4´,5,5´-hexachlorobiphenyl 
(PCB-153), and 2,2´,3,4,4´,5,5´-heptachlorobiphenyl (PCB-180) in mothers was estimated to sub-
sequently simulate infant blood, breast milk, and cord blood POP concentration. Simulations were 
then compared with corresponding measured levels through Spearman correlation analyses. 
re s u l t s: Predictions were highly correlated with measured concentrations for PCB-153, PCB-180, 
PCB-138, HCB, and p,p´-DDE (r = 0.83–0.96). Weaker correlations were observed for p,p´-DDT 
and β-HCH for which levels were near the limits of detection.
co n c l u s i o n: This is the first study to validate a PBPK model of POPs in infants on an individual 
basis. This approach will reduce sampling efforts and enable the use of individualized POP toxicoki-
netic profiles in the epidemiologic studies of POP adverse effects on child development.
key w o r d s : epidemiology, exposure assessment, infants, persistent organic pollutants, physiologi-
cally based pharmacokinetic modeling. Environ Health Perspect 117:481–487 (2009).  doi:10.1289/
ehp.0800047 available via http://dx.doi.org/ [Online 10 November 2008]Verner et al.
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presented herein was developed to generate 
individualized toxicokinetic profiles in infants 
exposed pre- and postnatally.
In this study, we aimed to develop a generic 
model to estimate infant exposure to POPs 
through placental transfer and breast-feeding 
and to validate the model using data on lev-
els of three polychlorinated biphenyl (PCB) 
congeners [2,2´,4,4´,5,5´-hexachlorobiphenyl 
(PCB-153), 2,2´,3,4,4´,5,5´-heptachlorobiphe-
nyl (PCB-180), and 2,2´,3,4,4´,5´-hexachlo-
robiphenyl (PCB-138)]; hexachlorobenzene 
(HCB); β-hexachlorocyclohexane (β-HCH); 
1,1-dichloro-2,2-bis(p-chlorophenyl)ethyl-
ene (p,p´-DDE); and p,p´-DDT measured 
in mothers and infants in the course of an 
infant cohort study in the Inuit population of 
Nunavik (Northern Québec, Canada).
Methods
The development of the PBPK model fol-
lowed a four-step approach: model repre-
sentation, parameterization, simulation, and 
validation. The PBPK model presented herein 
was based on a previous model (Verner et al. 
2008) modified to consider additional infor-
mation on events related to pregnancy, lacta-
tion, and infant physiology.
Model representation. The model repre-
sentation for the mother was described previ-
ously (Verner et al. 2008). Briefly, the maternal 
model was functionally described as a tissue 
network of nine compartments (liver, brain, 
adipose tissue, richly perfused tissues, poorly 
perfused tissues, mammary tissue, uterus, 
placenta, and fetus) (Figure 1). POPs were 
assumed to be fully absorbed through ingestion 
of contaminated food and their absorption 
was described as a direct input into the liver 
compartment. Excretion through lactation was 
represented as output from the mammary tis-
sue compartment.
To describe the exposure/toxicokinetics 
in infants, we integrated a five-compartment 
submodel (i.e., liver, adipose tissue, richly per-
fused tissue, poorly perfused tissue, brain) with 
the maternal model (Figure 1). Infant liver was 
defined as the first-pass organ where both POP 
intake from breast-feeding and POP metabo-
lism take place. Adipose tissue represented the 
main storage compartment for POPs. Richly 
and poorly perfused tissue compartments rep-
resented groups of organs that were lumped 
according to their perfusion rates and resi-
dence times. Finally, the brain was represented 
as a specific compartment, because it is the 
target organ in relation to potential neurode-
velopment deficits. The female infant model 
was conceptually different from the maternal 
model, because compartments relating to preg-
nancy and lactation (i.e., uterine, placental, and 
mammary tissues) were either physiologically 
irrelevant for males or kinetically irrelevant for 
females during the first year of life.
Absorption. As mentioned above, oral 
absorption of POPs for both mothers and 
infants was described as a direct input in the 
liver compartment. The assumption of 100% 
absorption is supported by high POP absorbed 
fractions, reported by McLachlan (1993) and 
Maruyama et al. (2003). We assumed dietary 
exposure to POPs in mothers to be a constant 
daily dose adjusted for body weight. Infant 
postnatal exposure to POPs was limited to the 
ingestion of contaminated breast milk up to 
12 months of age. Because of the lack of infor-
mation on mixed feeding (partial breast-feed-
ing), only the exclusive breast-feeding period 
was considered. Infant intake was calculated 
as follows:
  Intake = Cmilk × Qmilk,   [1]
where Intake is the hourly intake through 
breast-feeding in micrograms per hour, Cmilk 
is the POP concentration in milk (micrograms 
per liter), and Qmilk is the milk intake in liters 
per hour. 
Infant initial body burden was based on 
the assumption that intrauterine exposure to 
POPs is blood-flow limited. Because lipo-
philic POPs distribution is solely driven by 
their solubility in lipids, infant blood and 
tissue lipid-adjusted concentrations at birth 
were equal to lipid-adjusted levels in maternal 
blood at the time of delivery.
Distribution. The distribution of POPs in 
compartments was managed by both the blood 
flow and tissue:blood partition coefficients. 
This process was described by a set of mass 
balance differential equations (MBDE) that 
assume homogenous distributions in tissues, 
as follows:
 
,  [2]
where At represents the amount of chemi-
cal in the compartment (micrograms), Qt is 
the blood flow perfusing the compartment 
(liters per hour), Pt:b is the tissue:blood par-
tition coefficient for the compartment, and 
Ca and Ct stand for concentrations in arterial 
blood and the tissue (micrograms per liter), 
respectively. Venous and arterial blood con-
centrations were assumed to be equal, the lat-
ter being calculated as a weighed sum of tissues 
venous blood concentration:
 
,  [3]
where Ca is the arterial blood concentration 
(micrograms per liter), Qt is the blood flow to 
tissues (liters per hour), Cvt is the tissue venous 
blood concentration (micrograms per liter), 
and Qc is the cardiac output (liters per hour).
Metabolism. Metabolism was limited 
to the liver compartment, and the rate was 
described by the product of the hepatic extrac-
tion ratio (Eh), the liver blood flow in liters 
per hour (Ql), and the arterial blood concen-
tration in micrograms per liter (Ca) entering 
the compartment, as follows:
  RAM = Eh × Ql × Ca.  [4]
Figure 1. Conceptual representation of the mother–infant PBPK model. A previously published model 
(Verner et al. 2008) for the mother (left) was modified to integrate an infant submodel (right). Initial infant 
body burden was calculated as detailed in “Methods.” 
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The hepatic extraction ratio was calculated as 
a function of liver volume adjusted intrinsic 
clearance in liters per hour per kilogram liver 
(Cl int), blood flow to liver in liters per hour 
(Ql), and liver volume in liters (Vl):
 
.  [5]
Intrinsic clearance values were assumed to 
be equal in mothers and infants. Ontogenic 
changes in enzymes catalyzing POP biotrans-
formation were not included in this study but 
could easily be implemented in the future.
Excretion. Excretion of POPs through 
breast-feeding was detailed in our previous 
study (Verner et al. 2008). Briefly, POP 
excretion through breast milk was managed 
by milk flow out of the mammary tissue com-
partment and milk:blood partition coefficient. 
Placental transfer of POPs was modeled as an 
initial body burden in infants, where tissue 
and blood lipid-adjusted concentrations were 
equal to maternal plasma lipid-adjusted POP 
concentration.
Model parameterization.  Maternal 
parameters. Maternal parameters were those 
of the previously published model (Verner 
et al. 2008), with modifications for blood 
lipids during pregnancy as well as breast 
milk lipids and daily excreted volume. 
Blood lipid profile throughout pregnancy 
and postpartum period was modeled as a 
70% linear increase in neutral lipids from 
the start of pregnancy until delivery, and a 
linear decrease back to normal values over 
1.5 months postpartum. This profile was 
derived from data on triglycerides and cho-
lesterol throughout and after pregnancy 
(Chiang et al. 1995).
Breast milk volume and lipid content 
were modified from our previously published 
article. A better description of ingested milk 
volume as a function of both infant age and 
infant body weight was found in Arcus-Arth 
et al. (2005) and was modified as follows:
  Intake = –0.114 × Agei + 0.158,   [6]
where Agei is the infant age in years and 
daily milk intake is in liters per kilogram 
of infant body weight. According to this 
equation, the breast milk daily intake is 
assumed to be 0.158 L/kg of infant body 
weight at birth and to decline to 0.044 
L/kg of infant body weight at the age of 
12 months. Breast milk lipid composition 
was also modified: A logarithmic function 
was optimized on breast milk lipid fraction 
data from Bitman et al. (1983) for the first 
42 days and Arcus-Arth et al. (2005) for the 
period 3–12 months:
  Flmilk = 0.0034 × ln(Agei) + 0.0414,  [7] 
where Flmilk represents the fraction of lipids 
in milk, and Agei is the infant age in years. 
Given this equation, the fraction of lipids in 
breast milk at the time of delivery is set to 
approximately 0.0101 and rapidly increases to 
reach 0.0414 one year postpartum.
Infant parameters. Equations and param-
eters describing infant physiology were 
allowed to change as a function of sex, age, 
body weight, and body height. Age- and 
sex-specific organ volumes and blood flows 
are presented in Table 1. Tissue:blood and 
milk:blood partition coefficients were cal-
culated with the approach of Haddad et al. 
(2000), which showed that the distribution 
of chemicals with log octanol:water partition 
coefficient (Kow) values > 4 is driven solely by 
lipid fractions in tissues and blood:
 
,  [8]
where Pt/m:b is the tissue:blood or milk:blood 
partition coefficient, Flt/m stands for the frac-
tion of lipids in tissue or milk, and Flb repre-
sents the fraction of lipids in blood. Fractions 
of lipids in tissues and blood are shown in 
Table 2. Values for richly and poorly perfused 
tissues were calculated from volume-adjusted 
lipid fractions of organs they represent. 
Equations and values were taken from Price 
et al. (2003). Because no significant variation 
was seen in these compartments’ lipid frac-
tions during the first year of life, these values 
were kept constant.
Metabolism was parameterized from half-
life values as described previously (Verner 
et al. 2008). Briefly, half-life values were trans-
formed into liver volume-adjusted intrinsic 
clearance values (Table 3) to calculate hepatic 
extraction ratios.
Model simulation and validation. 
Variability assessment. To grasp the pos-
sible range of under- and overprediction we 
may expect due to interindividual variabil-
ity in sensitive physiologic parameters [sen-
sitivity analysis shown in the Supplemental 
Material (online at http://www.ehponline.
org/members/2008/0800047/suppl.pdf)], we 
performed Monte Carlo analyses on three 
Table 1. Physiologic parameters for male and female infants from birth to 12 months of age. 
Parameters  Sex  Equations
BSa  M & F  BW0.515 × (BH0.422) × 234.9
Volumes (L)   
  Liver (Vl)a  M & F  0.05012 × BW0.780
  Adipose tissue (Vat)a  M & F  0.91 × BW – (Vl + Vrp + Vpp + Vsk)
  Skin tissue (Vsk)a  M & F  0.664 × (BS/104) + 0.07850 × (BS/104)1.049
  Richly perfused tissue (Vrp)a  M  –0.01068 × AGEi + 2.038 × (BW2/BH)0.4014 – 0.2046 –Vl
  F  –0.01919 × AGEi + 3.193 × (BW2/BH)0.2657 – 1.374 –Vl
  Poorly perfused tissue (Vpp)a  M & F  Vt + Vh + Vsm
  Tongue (Vt)a  M & F  0.00119 × BW –0.0004302
  Heart (Vh)a  M   0.0000001017 × [(BH0.6640) × (BW0.3851) × 242.7]1.420
  F  0.0000001017 × [(BH0.6862) × (BW0.3561) × 242.7]1.420
  Skeletal muscle (Vsm)a  M  0.09561 × BW + 0.01601 × BH + 0.1097 × AGEi
  F  0.09563 × BW + 0.01650 × BH + 0.09102 × AGEi – 0.1642
  Brain (Vbrain)b  M  10 × (AGEi + 0.213)/(6.030 + 6.895 × AGEi)
  F  10 × (AGEi + 0.226)/(6.521 + 7.514 × AGEi)
Blood flows (L/hr)   
  Cardiac output (Qc)a  M  0.2519 × BW0.7609 × 60
  F  0.2508 × BW0.7815 × 60
  Liver (Ql)a  M  0.84 × Vl × 60
  F  Vl × 60
  Adipose tissue (Qat)a  M  0.0209 × Vat × 60
  F  0.0300 × Vat × 60
  Richly perfused (Qrp)a  M & F  QC – (Qpp + Qat + Ql + Qbrain)
  Poorly perfused (Qpp)a  M  (0.03 × (Vt + Vsm) + 0.73 × Vh) × 60
  F  (0.03 × (Vt + Vsm) + 0.96 × Vh) × 60
  Brain (Qbrain)c  M & F  – 0.0024 × AGEi
4 + 0.1305 × AGEi
3 – 2.4822 × AGEi
2 
    + 18.025 × AGEi + 15.197
Abbreviations: AGEi, age; BH, body height; BS, body surface; BW, body weight; F, female; M, male; Qat, blood flow to adi-
pose tissue; Qbrain, blood flow to brain; Qc, cardiac output; Ql, blood flow to liver; Qpp, blood flow to poorly perfused tis-
sue; Qrp, blood flow to richly perfused tissue; Vat, adipose tissue volume; Vbrain, brain volume; Vh, heart volume; Vl, liver 
volume; Vpp, poorly perfused tissue volume; Vrp, richly perfused tissue volume; Vsk, skin volume; Vsm, skeletal muscle 
volume; Vt, tongue volume. Equations are based on infant body weight, body height, body surface, and age. 
aModified from Haddad et al. (2006). bModified from Haddad et al. (2001). cData from Price et al. (2003)
Table 2. Fraction of lipids in infant tissues.
Tissue  Age (years)  Fraction of lipids
Blooda  0–1  0.005
Adipose tissuea  0  0.347
  0.5  0.472
  9  0.550
Livera  0  0.021
  1  0.041
Richly perfusedb  0–1  0.018
Poorly perfusedb  0–1  0.021
Braina  0  0.026
  1.5  0.061
aData from White et al. (1991). bCalculated as detailed in 
“Methods.” Verner et al.
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independent sensitive parameters relevant 
to POP toxicokinetics for infants exposed 
through breast-feeding (100 iterations). In 
this analysis, published SD values for the frac-
tion of lipids in infant adipose tissue (0.12), 
the fraction of lipids in breast milk (0.0032), 
and the daily ingested breast milk consump-
tion (0.038 L/kg infant body weight/day) 
were used to randomly assign parameter val-
ues in each iteration, assuming normal distri-
butions (Arcus-Arth et al. 2005; Bitman et al. 
1983; White et al. 1991).
We used body weight and height profiles 
for the 50th percentile taken from the Centers 
for Disease Control and Prevention (CDC) 
data as surrogate physiologic profiles for both 
mother and infant (Kuczmarski et al. 2000). 
The analysis was done for a woman giving birth 
to a girl at the arbitrary age of 25, followed by 
a 3-month breast-feeding period. Mothers were 
exposed to 10 ng/kg body weight/day of the 
highest and lowest half-life compounds used in 
this study (PCB-153 and p,p´-DDT).
Validation data set. Validation of the model 
was done using data on PCB-180, PCB-153, 
PCB-138, HCB, β-HCH, p,p´-DDE, and 
p,p´-DDT levels in Inuit mothers and infants 
from northern Québec (Canada). The cohort 
was described previously by Muckle et al. 
(2001). The subjects kept for the validation step 
were those for which sufficient information was 
available:
•	Mother	physiology	(prepregnancy	weight,	
height, age at delivery)
•	History of lactation (exclusive breastfeeding 
period)
•	Infant physiology (body weight and body 
height information for a period covering the 
time of infant plasma sampling)
•	Dates	of	sampling	(mother	and	infant	
plasma)
•	POP	concentrations	in	mothers	and	infants	
at 6 months of age (with levels above the 
limit of detection).
Simulations. To run lifetime exposure in 
each mother, the PBPK model required com-
plete body weight and body height profiles. 
Because maternal body height and weight were 
available only at one time before pregnancy, 
we used growth curves to infer lifetime profiles. 
This was done by assigning a percentile body 
height or body height profile from CDC data 
to fit the individual prepregnancy body weight 
and height. Maternal exposure was optimized 
to fit the lipid-adjusted POP level measured in 
plasma. Infant body weight and height were lin-
early interpolated between measurements taken 
at 0, 6, and 12 months. Simulated lipid-adjusted 
infant plasma (at 6 months of age), breast milk, 
and cord blood levels were then compared with 
measured levels through correlation analyses. 
Software. We performed PBPK modeling 
and simulations using ACSLXtreme software 
(Aegis Technologies Group, Inc., Huntsville, 
AL, USA). We carried out nonparametric 
correlation analyses (Spearman coefficients) 
using SPSS for Windows statistical package 
(SPSS Inc., Chicago, IL, USA).
Results
Monte Carlo simulations. We assessed pop-
ulation variability for given physiologic pro-
files and breast-feeding history using Monte 
Carlo simulations based on variability of three 
independent sensitive parameters (breast milk 
consumption, fraction of lipids in breast milk, 
and fraction of lipids in infant adipose tis-
sue). Simulations for PCB-153 and p,p´-DDT 
yielded distributions of toxicokinetic pro-
files in infants during their first 6 months 
(Figure 2). At the end of the breast-feeding 
period (3 months postpartum), the 5th–95th 
percentile values in infant blood concentration 
were 227–538 µg/kg lipids for PCB-153 and 
90–213 µg/kg lipids for p,p´-DDT. The 5th–
95th percentile ranges at 6 months of age were 
119–303 and 42–109 µg/kg lipids for PCB153 
and p,p´-DDT, respectively. These ranges indi-
cated an approximately 2.5-fold variability 
between the 5th and 95th percentiles.
Simulation of maternal POP toxicokinet-
ics. To simulate the lifetime toxicokinetics of 
POPs in mothers, exposure was optimized to 
fit plasma concentration in samples drawn 
around the time of delivery. Lowest and high-
est exposure values used to match maternal 
levels were kept for the determination of envi-
ronmental exposure ranges. Estimated maternal 
exposure ranges were (ng/kg body weight/day) 
as follows: 1.3–52.3 for PCB-153; 1.5–31.8 
for PCB-180; 0.9–34.9 for PCB-138; 1.6–58.9 
for HCB; 0.2–4.4 for β-HCH; 5.2–212.5 for 
p,p´-DDE; and 0.4–25.7 for p,p´-DDT.
Prediction of cord blood concentration. As 
mentioned above, cord blood lipid-adjusted 
concentration was assumed to be the same as 
maternal lipid-adjusted blood concentration 
at the time of delivery. Using this assumption, 
strong Spearman’s correlations (r > 0.90) were 
obtained for most POPs when comparing sim-
ulated values with measured values, as depicted 
in Figure 3. Weaker correlations were observed 
for p,p´-DDT (r = 0.79) and β-HCH (r = 
0.35). No systematic under- or overestimation 
was observed for cord blood levels prediction. 
Comparison could not be achieved for HCB, as 
this chemical was not analyzed in cord blood.
Prediction of breast milk concentra-
tion. Because breast-feeding was consid-
ered to be the exclusive route of postnatal 
exposure in infants for this study, simulated 
breast milk concentrations were compared 
with levels in samples collected approximately 
1 month after delivery. Most correlations had 
Spearman’s rho values above 0.90 (Figure 3). 
p,p´-DDT and β-HCH simulated breast milk 
levels had weaker correlation values of 0.72 
and 0.70, respectively. A slight tendency to 
under  estimate breast milk concentrations was 
observed for most compounds. 
Estimation of infant blood concentration 
at ~ 6 months of age. Infant blood levels were 
predicted considering both exposure through 
Table 3. Half-life and calculated liver volume–adjusted intrinsic clearance of POPs in infants and mothers.
Compounds  Half-life (years)   Intrinsic clearance (L/hr/kg liver)   Source of half-life value
PCB-153  27.5  0.0082601  Yakushiji et al. (1984)
PCB-180  9.9  0.0229504  Yakushiji et al. (1984)
PCB-138  16.3  0.0144328  Yakushiji et al. (1984)
HCB  6  0.0395820  To-Figueras et al. (1997)
β-HCH  7.6  0.0309631  Jung et al. (1997)
p,p´-DDE  15  0.0156840  Wolff et al. (2000)
p,p´-DDTa  5  0.0144328  Smith (1999)
aThe half-life value displayed was chosen arbitrarily for a range of 4.2–5.6 years in Smith (1999).
Figure 2. Blood POP level distributions in infants obtained from Monte Carlo simulations for (A) PCB-153 
and (B) p,p ´-DDT. Simulations were carried out by varying three independent sensitive parameters 
(100 iterations). Toxicokinetic profiles were simulated for a mother exposed to a constant dose of 10 ng/kg/
day and giving birth to a girl at 25 years of age, followed by a 3-month breast-feeding period. Simulations 
were performed for the highest and lowest half-life compounds in this study. 
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placental transfer and breast-feeding. Simulated 
toxicokinetic profiles matched measured infant 
blood POP concentration with high Spearman’s 
correlations (Figure 3). Plots of measured values 
on predicted values showed a slight system-
atic overestimation (Figure 3). Simulations of 
β-HCH toxico  kinetics in infants yielded incon-
sistent results, displaying a high variability that 
could not be explained by the model at low 
concentrations. Predicted blood concentrations 
fell within the 2.5-fold range variation defined 
in Monte Carlo simulations (between the 5th 
and 95th percentiles) for 88% (p,p´-DDE), 
85% (PCB-153 and PCB-138), 82% (HCB), 
75% (PCB-180), 67% (p,p´-DDT), and 66% 
(β-HCH) of individuals.
Discussion
In this study we aimed to build and validate a 
PBPK model for the characterization of infant 
exposure to POPs through placental transfer 
and breast-feeding. This work follows our first 
modeling paper on the assessment of lifetime 
POP toxicokinetics in human (Verner et al. 
2008) and focuses primarily on exposure in 
infants. The successful validation of our PBPK 
model within this study using data on mothers 
and infants from an Inuit population further 
supports the potential of this internal exposure 
assessment tool in epidemiologic studies.
This PBPK model based on individual 
physiology and breast-feeding period allows 
the integration of several concurrent physio-
logic events (e.g., pre- and postpartum 
changes in maternal physiology, lactation, 
infant growth) that are relevant to POP toxi-
cokinetics. Modeling simultaneous variations 
in volume and lipid composition of mater-
nal tissues and breast milk over time is criti-
cal in characterizing POP distribution and 
thus infant exposure. The determination of 
infant initial body burden is also essential to 
correctly assess perinatal exposure, because 
initial levels rapidly depurate due to infant 
growth. The toxicokinetic profiles depicted in 
Figure 4 show the close relationship between 
POP levels in maternal blood, breast milk, 
and infant blood. Another benefit of using 
PBPK modeling is the possibility of predict-
ing POP concentration in potential target 
tissues of newborns and infants. However, 
such estimates were not shown in the present 
study, as their validation would have required 
the sampling of infant tissues.
To estimate background exposure to 
POPs in mothers, the daily intake was opti-
mized so the simulated lipid-adjusted blood 
concentration reached the measured mater-
nal blood level. A study by Dewailly et al. 
(1996) estimated the mean daily PCB expo-
sure in Inuits to be 13.8 µg/day (i.e., a 230-
ng/kg body weight/day intake for an average 
60-kg woman). In their review, Van Oostdam 
et al. (2005) reported median daily intakes 
of 20 ng/kg body weight/day for HCB, 
40 ng/kg body weight/day for p,p´-DDT, 
and 50 ng/kg BW/day for PCBs in Inuits 
of Qikiqtarjuaq. The estimated daily expo-
sure ranges (nanograms per kilogram body 
weight per day) obtained in this study for 
p,p´-DDT (0.4–25.7), HCB (1.6–58.9), and 
the sum of the three PCBs (3.7–119) were 
comparable to these daily intake estimates, 
indicating that the PBPK model is fairly accu-
rate at estimating the maternal exposure to 
POPs. As reported previously (Verner et al. 
2008), daily intakes can be better assessed 
when considering pregnancies and lactation 
periods that precede the time of sampling, as 
well as dietary habits and temporal trends in 
Figure 3. Spearman’s correlations between predicted and measured lipid adjusted POP levels in infant 
plasma, cord blood, and breast milk. NA, not applicable. Dotted lines represent the unity slope. Correlation 
analysis for HCB levels in cord blood could not be conducted because this compound was not measured 
in this media.
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environmental levels. When available, such 
information could easily be integrated in the 
PBPK model.
Predicted cord blood, breast milk, and 
infant blood concentrations by PBPK model-
ing showed strong Spearman’s correlations 
with measured levels (see Figure 3). However, 
a minor discrepancy still remains between 
simulated and measured levels, indicating 
that sources of toxicokinetic variability are 
not accounted for within the model. Monte 
Carlo simulations showed that the infant toxi-
cokinetic profile is influenced by the variabil-
ity in breast milk lipids and volume, as well 
as by the lipid fraction in the adipose tissue 
compartment. Variability within these sen-
sitive parameters is not taken into account 
when simulating POP toxicokinetics, leading 
to potential errors in predictions. Simulated 
values fell within the 2.5-fold variability range 
for 66–88% of individuals used in this study, 
depending on the compound. This suggests 
that other factors such as inaccuracy in infor-
mation from questionnaires and variability in 
the analytic methods used to quantify POPs 
might affect model predictability. It is also 
possible that some parameters were incorrectly 
estimated, as the physiologic equations were 
derived from data on Caucasians, whereas the 
data set used in this study was on Inuit people. 
The under- or overestimation of infant adipose 
tissue volume might yield a systematic bias 
and other measurements to estimate this value, 
such as the sum of skin folds (Ayotte et al. 
2003), should be evaluated in future studies. 
Another source of error can arise from the 
fact that exposure to POPs through the inges-
tion of contaminated breast milk was limited 
to the exclusive breast-feeding period. Because 
of a lack of information, the period of mixed 
feeding (when the infant is fed both breast 
milk and formula) was assumed to be a period 
without breast-feeding, leading to a potential 
underestimation of infant exposure in cases 
with important mixed feeding. A detailed 
description of formula and milk consumption 
history would provide valuable information 
for the estimation of exposure through breast-
feeding during the mixed feeding period and 
allow the inclusion of partial breast-feeding in 
the model.
Correlations between predicted and meas-
ured levels were weaker for β-HCH and 
p,p´-DDT. These compounds are characterized 
by their shorter half-lives and levels in mothers 
and infants that are near the limits of detection. 
The impact of half-life alone on model inability 
to precisely estimate measured values is not 
likely to be the most influent factor, given that 
simulated levels of HCB (a compound with a 
shorter half-life than β-HCH) were strongly 
correlated to measured concentrations in infant 
plasma and breast milk. On the other hand, 
model accuracy might be limited when work-
ing with POP levels close to limits of detection, 
a phenomenon potentially caused by reduced 
precision in analytic methods at low POP 
concentration in samples. Predictions with 
β-HCH might have been influenced by the 
fact that this compound has a lower log Kow 
(3.81). Its value below the partitioning cutoff 
(i.e., log Kow = 4) for the method used in this 
study possibly led to a slight error in partition 
coefficients determination. Overall, caution 
should be exerted when using this model for 
compounds with levels near the limits of detec-
tion and/or that have low log Kow values.
Simulations slightly underestimated POP 
lipid-adjusted concentration in breast milk. 
This might be explained by the difference in 
approaches to adjust POP levels for lipids. 
Adjustment for blood lipids in the Ayotte 
et al. (2003) study was based on total lipids as 
described in Phillips et al. (1989), whereas the 
PBPK model used neutral lipid equivalents 
exclusively. Lipids in breast milk are composed 
almost solely of triacylglycerols (Jensen 1999), 
whereas lipids in maternal blood also contain 
significant levels of cholesterol and phospho-
lipids (Berghaus et al. 1998). Although tria-
cylglycerols and cholesterol are neutral lipids 
in which POP will be stored, phospholipids 
have a lipohydrophilicity similar to a mixture 
of 30% neutral lipids and 70% water (Poulin 
and Krishnan 1995). Therefore, including 
phospholipids in blood lipid content calcula-
tion leads to an artifactual difference between 
blood and milk lipid-adjusted POP concen-
trations. As only neutral lipid equivalents are 
considered in the PBPK model and POPs are 
assumed to be homogeneously distributed in 
lipids, simulated lipid-adjusted POP levels in 
blood and milk are equal. Thus, the underes-
timation of POP levels in breast milk can be 
explained at least partially by these different 
approaches in adjusting levels for lipid con-
tents. When information on whole blood and 
breast milk lipid composition is available, lev-
els should be adjusted on neutral lipid equiva-
lents rather than total lipids.
The results of this study showed the poten-
tial of PBPK modeling in estimating POP 
toxicokinetics in infants. Detailed informa-
tion on internal exposure, such as the timing 
and amplitude of the maximum concentra-
tion, can be harvested from the simulations 
(Figure 5). This could be an important input 
in epidemiology to study high exposure during 
hypothesized critical time windows. For exam-
ple, it was suggested that internal exposure to 
Figure 4. Examples of toxicokinetic profiles for PCB-153 in maternal blood, breast milk, and infant blood for different breast-feeding scenarios.
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PCB alters thyroid hormones levels (Chevrier 
et al. 2007). Disturbed thyroid levels in neo-
nates can result in several adverse health effects 
such as visual, motor, language, and memory 
impairment (Zoeller and Rovet 2004). Using 
only measured POP levels in 6-month-old 
infants to test an exposure-effect hypoth-
esis might be too limiting for the complete 
analysis of time- and dose-related responses. 
An approach using the maximum concentra-
tion (and the time when this concentration is 
reached) as well as the area under the curve 
for different time frames might provide crucial 
information on critical windows of exposure as 
well as dose–response relationships.
Overall, PBPK modeling was shown to be 
a relevant method to assess pre- and postnatal 
exposure to POPs. The presented model allows 
the prediction of infant exposure through pla-
cental transfer (cord blood level estimation at 
the time of delivery) and breast-feeding strictly 
from information on maternal blood levels 
and physiologic profiles that can be easily 
gathered from epidemiologic questionnaires. 
Moreover, this is the first study to validate a 
PBPK model of POPs in infants on an indi-
vidual basis. This study also successfully dem-
onstrates how our previously published model 
(Verner et al. 2008) adequately describes the 
lactational excretion of POPs in women. 
This PBPK modeling approach will permit 
the assessment of exposure to POPs in infants 
prospectively and retrospectively, therefore 
reducing sampling efforts and enabling the use 
of individualized POP toxicokinetic profiles 
in epidemiologic studies. Further research is 
planned to validate the model with other pop-
ulations, later life stages, and additional com-
pounds such as PBDEs. Researchers interested 
in collaborating with us or using our model 
are encouraged to contact us.
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